Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults (18 years or older) who are starting cisplatin chemotherapy (at a certain dose) for head/neck or lung cancer at one of the participating adult hospitals.
- Children older than 3 months who are starting cisplatin chemotherapy for any type of cancer at one of the participating children's hospitals.
- All participants must agree to take part in the study by giving their consent.
Who may not be able to join:
- People who already have chronic kidney disease or poor kidney function before starting the study (confirm with trial site for specific test values), or who have had a kidney transplant in the past.
- People who have used certain kidney-harming medications within the two weeks before starting cisplatin treatment (the trial team has a specific list of these medications).
- People who have received cisplatin chemotherapy before.
- People who have had certain types of radiation therapy (full-body radiation or radiation to the abdomen area) within the last month before joining the study.
- People who have previously had a stem cell transplant (bone marrow transplant).
- People who have any ongoing or sudden serious health condition — such as significant heart, lung, liver, kidney, or infection-related illness — that the doctor feels would make participation unsafe or unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 416-813-7654
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To identify patterns of metabolites and specific metabolites prior to and shortly after CisP treatment that predict AKI risk and identify the onset of AKI early (discovery cohort).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.